Paul Ts’o Ph.d.,Founder
Paul Ts’o was a full professor at Johns Hopkins University 1967-2002 and Director of Biophysics Division of JHU School of Public Health for eighteen years. He held the position of Senior Associate at Johns Hopkins since 2002. Dr. Ts’o was instrumental in founding Genta, a cancer therapeutics company. He was one of 1000 scientists from all fields whose publications were most cited during the period 1965-1978 and was a member of the Board of Scientific Counselors (Basic Sciences) for Intramural Programs, National Cancer Institute, 2006-2009.
John Hughes M.S
John attended the University of Minnesota where he received a Master’s Degree in Electrical Engineering (emphasis on bio-technology) and Bachelor Degrees in Economics and Electrical Engineering. Since 1987, John has been President of Rhythm & Hues Studios, a leading producer of computer generated character animation and visual effects for entertainment and advertising and the recipient of two Academy Awards for Best Visual Effects and several Science and Engineering Academy Awards. Headquartered in Los Angeles with additional facilities in Mumbai, Hyderabad and Kuala Lumpur, Rhythm & Hues has approximately 1000 employees worldwide.
Vivian Lauderdale, MBA, MS, RAC
Chief Operating Officer
Ms Lauderdale’s responsibilities include operations, quality systems and regulatory affairs for laboratory services and manufacturing. She has a Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society (RAPS) qualifying her to manage regulatory affairs for medical devices and pharmaceutical projects. She has over twenty-five years hands-on experience developing medical products – primarily in Quality Systems and/or Operations. Additionally, she is the founder and managing partner of SciBiz Services, LLC, a technical writing and biomedical business management company that she founded in 2000 which specializes in obtaining bio-medical government grants for small businesses that are exploring innovative high-risk biomedical technologies for future commercialization.
David Van Echo, M.D.
David A. Van Echo, M.D. has been Medical Director of CCCD since 2004. He is also the Director of HarborView Cancer Center at Harbor Hospital in Maryland. He has authored over 100 peer-reviewed articles and 150 abstracts/poster sessions in the field of cancer research. He was a senior investigator at NCI until 1981. From 1981 until 2005, he was Head of the New Drug Development Program and Chief Hematology/Oncology (1993-96) at the University of Maryland Cancer Center. This NCI supported program performed studies of HIV, anticancer drugs, animal pharmacology and Phase I, II and III clinical studies.
Stephen Lesko, Ph.D.
Stephen Lesko, Ph.D. was a member of the faculty of Johns Hopkins University for more than twenty years, where he established the University’s first imaging system. More recently he served as Research Director of Cell Works, Inc. In this capacity, he designed an imaging system used throughout the biotechnology industry to probe the characteristics of human cells. Dr. Lesko has one issued patent and has three additional patents pending concerning imaging and cancer diagnostics. He has authored/coauthored over 20 technical publications and abstracts/poster sessions.
Scott Deamond, B.S.
Scott Deamond has worked as a research scientist at Johns Hopkins University for twenty-five years. He has demonstrated expertise in laboratory management, regulation and the application of diverse scientific instrumentation. Mr. Deamond currently manages data compilation, interpretation and lab imaging procedures at CCCD. He has authored/coauthored over 23 technical publications and abstracts/poster sessions.